Core Insights - Eli Lilly raised its full-year profit and revenue forecasts due to strong demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro, surpassing third-quarter earnings estimates [1][5] - The company's shares increased over 5% in premarket trading, despite concerns regarding drug price negotiations with the Trump administration [1][2] Company Performance - Zepbound generated sales of $3.6 billion in the reported quarter, exceeding analysts' expectations of $3.23 billion, although higher demand was partially offset by lower realized prices [4] - Mounjaro sales reached $6.5 billion, surpassing the average analyst expectation of $5.73 billion [5] - For the quarter, Eli Lilly reported earnings of $7.02 per share on an adjusted basis, significantly above the analysts' average estimate of $5.69 [6] Future Projections - Eli Lilly expects adjusted earnings per share for the year to be between $23.00 and $23.70, an increase from the previous forecast of $21.75 to $23.00 [5] - Annual revenue is projected to be between $63 billion and $63.5 billion, up from the earlier forecast of $60 billion to $62 billion [6] Market Context - The weight-loss drug market is anticipated to reach $150 billion by the end of the decade, with Eli Lilly competing closely with Novo Nordisk [2] - The U.S. government's "most favored nation" policy aims to align U.S. drug prices with those in other wealthy nations, which may impact future pricing strategies for drugmakers [2]

Core Insights - Eli Lilly raised its full-year profit and revenue forecasts due to strong demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro, surpassing third-quarter earnings estimates [1][5] - The company's shares increased by 7% in premarket trading following the announcement [1] Financial Performance - Eli Lilly reported Zepbound sales of $3.6 billion for the quarter, exceeding analyst expectations of $3.23 billion [4] - The company adjusted its earnings forecast to $23.00 to $23.70 per share for the year, up from a previous estimate of $21.75 to $23.00 per share [5] - For the quarter, Eli Lilly earned $7.02 per share on an adjusted basis, significantly higher than the analysts' average estimate of $5.69 [5] Market Context - The weight-loss drug market is projected to reach $150 billion by the end of the decade, with Eli Lilly competing with Novo Nordisk for market leadership [2] - The U.S. government is implementing a "most favored nation" policy, which may impact drug pricing strategies for companies like Eli Lilly [3]